Hopfner Robert Lorne

DirectorInozyme Pharma, Inc. (INZY) · full profile →Form 4 · filed Jul 3, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 1, 2025Tender(U)2.9M$4.00$11.7M0
Jul 1, 2025Tender(U)1.6M$4.00$6.3M0

Transaction Codes

U
See SEC Form 4 code table

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-094089) within minutes of acceptance. Every field above traces to the original document. Verify it directly: